Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 18/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132359 | 0.95 | P2RX7 (0.54) | P2RX7CYP3A4TSHRMCHR1 | |
| SCHEMBL5131756 | 0.87 | P2RX7 (0.53) | P2RX7MCHR1 | |
| SCHEMBL5128962 | 0.86 | P2RX7 (0.47) | P2RX7MCHR1 | |
| SCHEMBL5123854 | 0.85 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL5126501 | 0.85 | P2RX7 (0.56) | P2RX7MCHR1 | |
| SCHEMBL5132275 | 0.85 | P2RX7 (0.58) | P2RX7CYP3A4 | |
| SCHEMBL5122915 | 0.81 | P2RX7 (0.53) | P2RX7 | |
| SCHEMBL5132358 | 0.80 | P2RX7 (0.60) | P2RX7CYP3A4 | |
| SCHEMBL5131429 | 0.79 | P2RX7 (0.56) | P2RX7CYP3A4MCHR1 | |
| SCHEMBL5123905 | 0.79 | P2RX7 (0.45) | P2RX7MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | claimed |
| EP-1651610-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009968-A1 | QUINOLINE DERIVATES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | WO | claimed |
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058293-A1 | Quinoline Derivates and Their Use in Therapy | NQO2, RECQL, CHRM1 | P2RX7 91/4885CYP3A4 119/4885TSHR 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.